TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04006054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .
Study: NCT02358473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mogamulizumab
Description: Mogamulizumab will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered by IV infusion.
Study: NCT03267277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Sodium thiosulfate is a calcium chelator
Study: NCT04079296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)
Study: NCT04335253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS884448
Description: Multiple Ascending Dose
Study: NCT04413071

Intervention type: OTHER
Intervention: Passed infection of SARS-CoV-2
Description: This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.
Study: NCT03659266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic walking rehabilitation by Lokomat®
Description: Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic walking rehabilitation by Lokomat®
Description: Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional walking rehabilitation
Description: 5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional walking rehabilitation
Description: 5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
Study: NCT00818610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta lactam (amoxicillin / clav. acid OR cefuroxime)
Description: 1.2 g 4x/d OR 1.5 g 3x/d IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)
Description: 1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
Study: NCT03028311

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography
Description: Undergo angiography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed Tomography
Description: Undergo SPECT-CT

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Planar Imaging
Description: Undergo planar imaging

Intervention type: RADIATION
Group type: OTHER
Intervention: Radioembolization
Description: Undergo radioembolization

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT-CT

Intervention type: RADIATION
Group type: OTHER
Intervention: Technetium Tc-99m Albumin Aggregated
Description: Given via arterial catheter
Study: NCT04810143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitra Microsampler
Description: an FDA Class I medical device for direct specimen collection of blood or other biological fluids
Study: NCT03028311

Intervention type: OTHER
Group type: OTHER
Intervention: Yttrium Y 90 Resin Microspheres
Description: Given via arterial catheter
Study: NCT03459287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEPT
Description: Pathogen reduced RBCs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional RBCs
Study: NCT03768414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT02647125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huachansu
Description: Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: thoracic radiation
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiation
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Study: NCT03290937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies
Study: NCT02822313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987518)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-76_V27-006)
Study: NCT04374851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polaris miniRITE BTE
Description: The Polaris device is programmed with computer software to match the Hearing loss of the participant.
Study: NCT03290937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV
Study: NCT03672331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mammogram
Description: Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Mammogram
Description: Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomosynthesis
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Tomosynthesis
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment
Study: NCT05025059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in coaching sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Perform walking exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Perform strength exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive WWE workbook and Growing Stronger Strength Training Program instruction manual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Maintain exercise log

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear fitness tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT00780195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: 2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: 2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: 2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: 2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
Study: NCT03740048

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer Oral Product
Description: Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
Study: NCT02296164

Intervention type: DRUG
Intervention: Valchlor
Description: Valchlor gel 0.016%
Study: NCT02495428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Method
Study: NCT03549923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous CRRT
Description: The patients in the simultaneous CRRT group will receive CRRT within 24 hours after the initiation of ECMO support.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional-indication CRRT
Description: The patients in the conventional-indication group will not receive CRRT until the patient demonstrates AKI and fulfills any one of the criteria of the conventional CRRT indication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The patients in esmolol group will receive a continuous esmolol infusion in addition to the standard care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
Study: NCT03327493

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biological
Description: We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~1. Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~2. Lymphocytes Th1/Th2 pattern by flow cytometry~3. Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~1. Hemodynamic parameters~2. Cumulated doses of catecholamines~3. Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)
Study: NCT02799836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blindfold
Description: Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
Study: NCT02268890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
Study: NCT04595071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice Activated Prosthetic Interface (VAPI) Controller
Description: A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
Study: NCT02873871

Intervention type: DEVICE
Group type: OTHER
Intervention: Standardized compressive dressing
Description: Standardized compressive dressing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostasis with TerumoBand®
Description: Hemostasis with TerumoBand®
Study: NCT01672645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIC7-001
Description: Intramuscular, multiple dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIC7-003
Description: Intramuscular, multiple dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (0.9% sodium chloride)
Study: NCT04559568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3522348
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3522348
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally to some participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered orally to some participants.
Study: NCT04374851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viron miniRiTE BTE
Description: The Viron Hearing device is programmed with computer software to match the Hearing loss of the participant.
Study: NCT02784951

Intervention type: DRUG
Intervention: Red blood cells (0Rh D-neg)
Description: Fresh produced RBC

Intervention type: DRUG
Intervention: Whole blood (O Rh D-neg K-neg)
Description: Fresh produced WB

Intervention type: DRUG
Intervention: Freeze dried plasma (LyoPlas)
Description: (LyoPlas N-w (German Red Cross)
Study: NCT02122016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartCare
Description: Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional weaning protocol
Description: A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
Study: NCT04175223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx
Description: probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months
Study: NCT05708911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal exerciser
Description: Pharyngo-esophageal manometry during lateral fluoroscopy
Study: NCT01559753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin
Description: All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~* Beta-Lactams:~  * Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~ * Ceftriaxone : 2 g OD during 3 days, then 1 g OD~ * Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~* Aminoglycosides~  * Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~ * Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~ * Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Study: NCT04877626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemeter plus lumefantrina vs artesunato plus amodiquina
Description: Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemeter plus lumefantrina vs artesunato plus amodiquina
Description: Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)
Study: NCT01161940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizatidine
Description: Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axid
Description: Axid 300 mg Capsules of Reliant Pharmaceuticals, US
Study: NCT03210948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RTE-guided EUS-FNA
Description: Fine needle aspiration with 25 gauge needle under RTE-guidance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EUS-FNA
Description: Fine needle aspiration with no RTE guidance
Study: NCT01384175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesia
Description: Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural infusion
Description: Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled epidural analgesia
Description: Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
Study: NCT02473081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention
Description: Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care was given by their family physicians.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care was given by their family physicians.
Study: NCT01667900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Study: NCT01559753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: compare 8 to15 days of antibiotic treatment
Description: All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compare 8 to15 days of antibiotic treatment
Description: All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)